Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
KPKaryopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTI)

NASDAQ Global Select · Currency in USD
$0.52 ▼ -0.03 (-5.24%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.49 ▼ -0.03 (-5.06%)
After hours: Oct 23, 7:57 PM ET

Summary

Previous Close
$0.55
Open
$0.54
Day's Range
$0.44 – $0.54
52 Week Range
$0.31 – $10.99
Volume
1,963,966
Avg. Volume
1,570,318
Market Cap
$11.74M
Beta (5Y Monthly)
1.04
PE Ratio (TTM)
--
EPS (TTM)
-$7.77
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$9.50

Profile: Karyopharm Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
228
CEO
Richard A. Paulson

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate -$1.16 · Revenue est. $33.54M
DateEst.Actual
Aug 13, 2026-$1.37-$2.32Miss
May 14, 2026-$1.45-$1.24Beat
Feb 12, 2026-$2.26-$5.68Miss
Nov 3, 2025-$3.47-$3.82Miss
Aug 11, 2025-$3.80-$4.32Miss
May 12, 2025-$4.21-$2.77Beat

Analyst view

Consensus price target
$9.50 ▲ +1,735.7%
Range $3.00 – $16.00
Rating: Buy
Buy 65% · Hold 25% · Sell 10%

Get free alerts on KPTI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.